Summary A modified tetrazolium reduction assay (MTT) was used to assess the relation between HLA class I antigen expression on tumour cells and their susceptibility as a target for non-MHC restricted LAK/NK cytotoxicity using interleukin-2 activated peripheral blood mononuclear cells (MNC) from normal individuals. At 20/1 effector/target ratio this ranged from no killing to 77%. The efficiency of killing was dependent on duration of effector cell culture with IL-2, peaking at day 10 and declining thereafter. This killing could be enhanced by addition of other cytokines including interferons alpha, beta and gamma.
There is increasing recognition that abnormalities in Major Histocompatibility Complex (MHC) antigens may be a factor for tumour escape from immunosurveillance (for review see . Reports suggesting that correction of these defects in tumour cells either by cytokine gene transfection (Gansbacher et al., 1990) or MHC gene transfection (Hui et al., 1984) induced immunity in recipients that enables them to reject parental untransfected tumour cells, offer real hope that genetic engineering could provide a cost effective approach to treatment of cancer.
Critical to the hypothesis of primacy of T cell immunity in resistance to cancer is the occurrence of specific MHC restricted anti-tumour cytolytic T lymphocytes (CTL) . Though these can be demonstrated in a minority of melanomas with apparently normal class I expression but over expression of non-functioning class II (Alexander et al., 1989) and the occasional other tumour under certain conditions (Lee et al., 1978; Belldegrun et al., 1988) , most adult solid tumour patients only show lymphokine activated killer (LAK) and natural killer (NK) cytotoxicity (Itoh et al., 1988; Nouri et al., 1991) possibly a reflection of their degree of aberrant class I expression. NK activity was first described by Kiessling et al. (1975) . Because some tumour cells, such as Daudi were consistently resistant to NK cytotoxicity, it was the discovery that IL-2 activated lymphocytes were cytotoxic for Daudi that led to the definition of LAK cells (Grimm et al., 1982) . It is now thought that LAK represents an activated form of NK cytotoxicity (Lange et al., 1991) and are involved in protection against experimental animal tumours (Mule et al., 1984) and in leukaemia in man (Archimbaud et al., 1991) .
There has been considerable controversy over the influence of class I antigen on LAK/NK killing. Some authors (Karre et al., 1986; Lobo & Spencer 1989; Maziarz et al., 1990) have demonstrated an inverse correlation, while others (Pena et al., 1989) of cell lines with varying degrees of class I antigens was investigated together with a study of the effect of correcting HLA class I defect on class I negative tumour line by gene transfection.
Materials and methods
Interferons, monoclonal antibodies, plasmids and cell lines etc Interferon a, P and y were obtained from Wellcome, ASTA Pharma (Bioferon) and Biogen respectively. Monoclonal antibodies (Mabs) were W6/32 (Brodsky et al., 1979, detects all P2m-associated HLA-A,B,C antigens) and L243 (HB55, Lampson & Levy 1980, detects class II antigens) . The pp2m-13 plasmid contains P2-m gene and was kindly donated by Dr E.J. Baas (Dept Cellular Biochemistry, The Netherlands Cancer Institute) and marker gene pSV2neo by Dr G. Reynolds, Cancer Immunology Laboratory, ICRF, Oxford). Cell lines Fen, Ha and Lan were in-house established lines from tumour biopsies of patients with transitional cell carcinoma, teratoma and seminoma respectively. For cell lines J82, Wil, RT4, Scaber, RT112, Tera I, Tera II, EP2012, 5637, SKV14 and lines see reference (Nouri et al., 1992a) The MNCs from normal individuals were separated using density gradient technique (Lymphoprep, Nycomed, Pharma), as described previously (Nouri et al., 1991) . The interface cells were aspirated washed and stimulated with IL-2 (100 u ml-', Biogen) for 72-96 h (unless otherwise stated) at 37°C. These activated cells, which are known to have both LAK and NK activities, were washed and resuspended at the required density to be used as effector cells (E).
Tumour infiltrating lymphocytes (TILs) were isolated from tumour biopsies as described previously (Nourn et al., 1991 (v/v) triton x 100 in water and the degree of radioactivity in the supernatants was measured using a gamma counter.
CYtotoxicitY using MTT reduction assai'
The use of MTT reduction assay for assessment of cytotoxicity has previously been reported (Hussain et al., 1992) . This was carried out using the modified MTT (3-[4,5-Dimethylthiazol-2yl]-2,5 diphenyl tetrazolium bromide) assay described by Mosmann (1983) . Exponentially growing cells were treated with trypsin (0.05%) + EDTA (0.02%) for 5 min, washed resuspended in RPMI containing 10% FCS and plated at 10 x 103/well in flat-bottomed microtitre plates (Nunc). Effector cells i.e. IL-2-activated MNCs were added to give effector/target (E/T) ratios of 5/1, 10/1 or 20/1 and were incubated for 4 h at 37°C. After incubation, plates were washed with fresh medium plus 2% FCS and the remaining cells were loaded with 10 Al/well of 5 mg ml-MTT plus 100 Al/well of medium and incubated for 3 h at 37°C. After the incubation medium was removed and 100 Al of acidified (0.04 M HCI) isopropanol was added, and the cells were incubated for 30 min at RT followed by the reading of the plate by an ELISA reader with 570 nm filter. TransJection Transfection was carried out using Lipofectin technique as described previously (Boucraut et al., 1991 Number of days in culture (1,627 ± 288 cpm). The LAK/NK activity varied from target to target and when assessed using the Spearman-Rank correlation coefficient, there was no statistically significant correlation between the class I antigen and efficiency of killing at 20/1 and 10/1 and 5/1 E/T ratios (Table I) . However, significant killing of tumour lines expressing lower class I antigens was observed when LAK/NK cells were tested against different targets at lower E/T ratios (Table II) . Correlation with class II antigens after IFNTy (100 u ml-') stimulation of the target cells was less informative (Table III) and even after splitting the cells into higher and lower inducer there was no significant correlation with LAK/NK killing.
Correction of missing class I antigen and its effects on efficiency of LAK/NK killing If the intensity of class I antigen expression is an important factor for LAK/NK killing, the introduction of missing class I antigens into a class I negative tumour target ought to decrease their susceptibility to LAK/NK killing. In our previous study we have demonstrated that bladder cell line Fen lacks P2 microglobulin (Nouri et al., 1992b) . After transfection with the missing 132m gene and selection with Geneticin, positive and negative cell clones were expanded and tested for susceptibility to LAK/NK killing. As can be seen from Table IV the level of binding for class I antigens before and after transfection were 132 ± 20 and 2,000 ± 48 cpm respectively. At higher E/T ratios (20/1) the restoration of class I antigens did not have a significant protective effects on LAK/ NK killing (36% vs 45% respectively). However, at low E/T ratio 1/1 the restoration of class I expression was associated with less killing.
Effects of cytokines on target cells Cytokines like interferons are known to upregulate MHC antigens. Experiment was set up to investigate the changes in the susceptibility of class I negative tumour target Fen after 48 h of IFN stimulation. As can be seen from Figure 2 , there was a significant increase in the susceptibility of the cells in response to IFNs. The percent increase in the killing for E/T ratios of 20/1 and 10/1 for IFN a, P and y treated cells were 30, 47, 44 and 6, 20 and 18 respectively indicating that all three IFNs increase susceptibility of target cells to killing. In addition, it was also found that the effector cell treatment with these IFNs increased their killing potential (Figure 3 ). This resulted in an increase of up to 20% over and above that with IL-2 alone and this may be a factor for their As can be seen from Table V . The addition of both antibodies increased the target killing by as much as 18% indicating that the increase target killing by anti-class I antibody is not class I antigen specific and may be due to the FcR-mediated killing.
Discussion
The results of this investigation have demonstrated that there was a large variation in the efficiency of LAK/NK killing of different individuals against the same tumour target and the same individual against different targets and this was at its maximum during the first week to 10 days of culture. The results also demonstrated that there was no inverse correlation between the LAK/NK killing and the intensity of class I antigen when the cytotoxicity assay was performed at high E/T ratios whereas at lower E/T ratios the class I negative tumours were found to be better targets. Specific CTL was discovered long before LAK/NK cells and shown to be restricted by MHC class I antigens (Zinkernagal et al., 1979) . NK in contrast, were only discovered from what were thought to be false positive reactions in negative controls for CTL assays (Carlson & Wegman 1977) . The specificity of CTL were refined by T cell cloning and shown to use the alpha/beta dimer of the T cell receptor (TCR, McMichael et al., 1988; Moss et al., 1991) and, unlike LAK/NK activity (Gorelik et al., 1988) , could be inhibited by antibodies to HLA class I (Salter et al., 1989) . The demonstration that cloned MHC restricted tumour infiltrating lymphocytes from melanomas could circulate and home to metastases in association with their rejection (Rosenberg et al., 1990 ) is to date the most convincing evidence that Results are expressed in % specific killing. Effector cells from two individuals (A and B) were mixed with target cells pre-treated with IFN y for 48 h. Antibodies W6/32 (anti-class I) and HB55 (anti-class II) were added in 100 LIl at the beginning of 4 h killing period.
anti-tumour immune specificity exists in man.
LAK/NK, were originally referred to as NK and were found to exist spontaneously in peripheral blood without the need for preactivation (Gorelik et al., 1988) . However, when recombinant cytokines and particularly IL-2 became available and the cytotoxic cells induced found to be more active against tumours such as Daudi which were consistently negative with NK cells they were given a separate name i.e. Lymphokine Activated Killers or LAK (Grimm et al., 1982) . However more recent research using lymphocyte differentiation markers and studies of their cytotoxic mechanism suggest that LAK/NK are probably the same cell (Lange et al., 1991) and the differential cytotoxicity may only reflect the degree of activation or differentiation from a common stem cell.
The results of this paper have demonstrated that at high E/T ratios LAK/NK activity does not show an inverse correlation with the degree of class I loss as has been demonstrated by some authors (Lobo & Spencer 1989; Maziarz et al., 1990) and that the correction of these antigens by cytokine treatment or transfection does not alter LAK/NK activity. Our findings support the views of Pena et al. (1989) who demonstrated that the efficiency of LAK/NK killing was independent of MHC class I antigen expression, and those by Aosi et al. (1991) who demonstrated that restoration of MHC class I antigens by addition of exogenous immunogenic peptides did not effect the efficiency of NK killing on target cells expressing both heavy and light chains of class I antigens but were negative with W6/32 antibody.
A possible explanation for these conflicting results, which might also explain why our data at low E/T ratio did show an inverse correlation between HLA class I level and LAK/ NK cytotoxicity (Table I) was reported by Storkus et al. (1991) . They demonstrated that transfection of some polymorphic class I genes such as HLA-A3, HLA-B7 and HLA-B27 into a class I negative tumour cell line had a protective effect on NK lysis, whilst other such as HLA-A2 did not, suggesting that conformational structure of different polymorphic class I antigens may influence the efficiency of its blocking effect on NK killing.
Our working hypothesis in explaining the contradictory reports is that the over-riding factor for controlling the non-MHC restricted LAK/NK killing is a receptor/target interaction independent of the mechanism regulating class I expression. However under circumstances when receptor expression is low, certain class I molecules as demonstrated by Storkus et al. (1991) would have conformational masking effect, hence becoming the limiting factor for the killing. On the other hand when receptors are in excess LAK/NK lysis occurs whatever the level of class I expression.
As yet the clinical relevance of these cells is unclear and their role in resistance to cancer is still controversial. While there was some suggestion that they were clinically significant from the studies of Rosenberg et al. (1989) whose clinical trial in melanoma demonstrated that IL-2 plus LAK/NK was more effective than IL-2 alone in terms of durable complete remission, his results in renal cell cancer were not significant and overview of pooled results in renal cell cancer failed to demonstrate any advantage of combination therapy over the results from IL-2 alone .
To better clarify our uncertainty about the role of LAK/ NK in vivo, more work including specific blocking and augmentation experiments in vitro and in vivo are needed to identify the target recognition molecules and receptor mechanism involved. 
